ICON Acquires Timaq Medical Imaging inc
24 Mai 2010 - 10:00AM
Business Wire
ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has acquired Timaq Medical Imaging, a leading European provider
of advanced imaging services to pharmaceutical and biotech
firms.
Headquartered in Zurich, Switzerland, Timaq was co-founded in
2003 by Gustav von Schulthess MD, PhD, MD hon, Chairman of
Radiology and Director of the Nuclear Medicine Department at the
University Hospital of Zurich. Professor von Schulthess is one of
the pioneers of combined PET/CT imaging and was lead director of
the first clinical PET/CT in the world in March 2001.
The acquisition of Timaq strengthens ICON's existing medical
imaging capabilities. ICON is a leader in the use of the core
imaging laboratories and has conducted over 500 imaging trials on
behalf of clients across the world.
"The acquisition of Timaq will complement our existing US
operations by giving ICON a European base for our Medical Imaging
operations,” commented Ted Gastineau President, ICON Medical
Imaging. "Alongside the immediate access to an experienced imaging
team, Timaq's strong links to leading medical institutions gives us
access to important scientific expertise in the imaging field that
will bring significant benefits to our clients."
"We are excited to be joining ICON," commented Gustav von
Schulthess. “Together we can enhance and expand the range of
imaging services we offer our clients, while ICON's global
footprint will enable us to support even the largest multi-country
imaging studies. We look forward to working closely with ICON's
imaging team to continue providing innovative imaging solutions
that can help expedite clients' drug development projects."
Notes to Editors:
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 69
locations in 39 countries and has approximately 7,300 employees.
Further information is available at www.iconplc.com.
About ICON Medical Imaging
ICON Medical Imaging, a division of ICON plc, provides medical
imaging based product development services to the pharmaceutical,
biotechnology and medical device industries and has assisted over
100 companies in hundreds of clinical trials resulting in more than
20 NDA/BLA submissions for regulatory approval.
ICON/ICLR-F / SOURCE: ICON plc
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024